FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Neurotune

Neurotune Strengthens Management

14-Apr-2011 - Neurotune AG announced personnel changes in its board of directors as well as management. Dr. Raimund Eckel will form the Board of Directors together Mr. Gerhard Musshafen and Dr. Bruno Oesch (Chairman). Furthermore, Dr. Armin W. Mäder, former CFO of Neurotune assumes the CEO position of ...

New members for Neurotune's Board of Directors

03-May-2010 - The shareholders of Neurotune AG have elected Dr. Anders Härfstrand and Heinrich Rotach as new members of the board of directors at their annual general assembly on April 21, 2010. Anders Härfstrand is a medical doctor with extensive experience in neuropharmacology and an excellent track record ...

AIDS pain Pfizer +3

Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients

18-Aug-2009 - Neurotune AG has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication. Neurotune’s Phase II trial (8-week, randomized, double-blind, ...

clinical trials HIV neuropathic pain +3

Change in the Management of Neurotune AG

28-Jan-2009 - Neurotune AG announced a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer from Dr. Andreas J. Schulze, who joined Neurotune in 2005 and is holding the position of CEO since 2006. Andreas J. Schulze will leave at his request ...